- 11:00 AM
In recent years we have seen significant regulatory changes in Canada that may affect market access of new drugs and biologics. As we look ahead to 2021, the legal experts at Smart & Biggar report on the recent developments to help innovative life sciences companies navigate the Canadian patent and regulatory landscape.
Smart & Biggar partners Daphne Lainson, Nancy Pei and David Schwartz recorded this timely update on patented medicines in Canada on Thursday, September 10th, including:
Patented medicines pricing reform
- Status of legal challenges to the amended Patented Medicines Regulations
- Coming into force of the new pricing regime of the Patented Medicine Prices Review Board (PMPRB)
- Implications of new law for grandfathered products, line extensions, “gap” drugs and new patented drugs
Patent term extension
- Recent jurisprudence concerning Certificates of Supplementary Protection
- Update on Patent Term Adjustment
Patent law changes
- Patent and patent application maintenance: new risks, greater certainty
- New options for maintaining pendency
- COVID-19 “compulsory licensing”